MESENCHYMAL STEM CELL THERAPY FOR INFARCT PROJ 3 2009

间充质干细胞治疗梗死项目 3 2009

• 批准号: 8168213
• 负责人: Chuanxi Cai
• 金额: $ 18.45万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8168213
• 关键词: Cardiac; Cardiomyopathies; Cardiovascular system; Computer Retrieval of Information on Scientific Projects Database; Coronary Arteriosclerosis; Funding; Grant; Heart failure; Infarction; Institution; Mediating; Mesenchymal Stem Cells; Myocardial Infarction; Myocardial Ischemia; Nature; Research; Research Personnel; Resources; Source; Therapeutic; United States National Institutes of Health; diabetes mellitus therapy; diabetic; diabetic patient; repaired; stem; stem cell therapy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nearly two-thirds of diabetics suffer from overt cardiovascular conditions, including coronary artery disease, myocardial infarction (MI), and cardiomyopathy. Despite the known systemic nature of diabetes, therapy for MI and ischemic cardiomyopathy are often not specifically tailored for diabetics, and the feasibility and efficacy of stem cell therapy for infarct repair in diabetic patients remains unclear. Although mesenchymal stem cells (MSCs) have been shown to induce infarct repair, the results have been variable and mechanisms remain controversial. The variability in MSC-mediated cardiac repair might have stemmed from the fundamentally heterogeneous nature of unfractionated 'MSCs'. We hypothesize that the use of a homogenous antigenically-defined MSC subpopulation with greater endothelial and cardiomyogenic differentiation potential and greater ability to secrete cardioprotective factors will result in superior cardiac repair in diabetics. These studies will identify the best MSC to use for infarct repair specifically in diabetics, and the results would have enormous therapeutic implications for diabetic patients with ischemic heart disease and post-MI heart failure.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 近三分之二的糖尿病患者患有明显的心血管疾病，包括冠状动脉疾病、心肌梗死 (MI) 和心肌病。尽管糖尿病的全身性已知，但心肌梗死和缺血性心肌病的治疗通常不是专门针对糖尿病患者的，并且干细胞疗法用于糖尿病患者梗塞修复的可行性和功效仍不清楚。尽管间充质干细胞（MSC）已被证明可以诱导梗塞修复，但结果各不相同且机制仍存在争议。间充质干细胞介导的心脏修复的变异性可能源于未分割的“间充质干细胞”的根本异质性。我们假设，使用具有更大的内皮和心肌分化潜力以及更强的分泌心脏保护因子的能力的同质抗原定义的 MSC 亚群将导致糖尿病患者获得更好的心脏修复。这些研究将确定用于糖尿病患者梗塞修复的最佳 MSC，其结果将对患有缺血性心脏病和心肌梗死后心力衰竭的糖尿病患者产生巨大的治疗意义。